Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 9Completed 9Recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 4Ovarian Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Skin Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Pleural Effusion, Malignant 2Penile Neoplasms 2Oropharyngeal Neoplasms 2Neuroblastoma 2Myelodysplastic Syndromes 2Mesothelioma, Malignant 2Leukemia, Myeloid 2Leukemia 2Hematologic Neoplasms 2Carcinoma, Merkel Cell 2Anus Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 8Nivolumab 6Ipilimumab 6cemiplimab 4aldesleukin 3Interleukin-2 3fludarabine 2Specimen Handling 2Niacinamide 2HhAntag691 2Cyclophosphamide 2Blood Specimen Collection 2Biopsy 2trametinib 1spartalizumab 1sonidegib 1pertuzumab 1lifileucel 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1dabrafenib 1brodalumab 1atezolizumab 1Vitamin A 1Trastuzumab 1Tissue Banks 1Surgical Procedures, Operative 1Sunscreening Agents 1Standard of Care 1Second Harmonic Generation Microscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Skin Neoplasms × aldesleukin × Clear all
NCT02621021 2026-05-08

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
170 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
29 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT07288073 2026-02-13

TIL Therapy in cSCC and MCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
14 enrolled
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡